Maryland is currently home to 2680 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the pr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection
NCT06168669
Recruiting
Purpose: To validate the safety and effectiveness of xBar monitoring tool for detection of post-operative anastomotic leaks in subjects undergoing rectal/sigmoid resections with anastomosis. The clinical team is blinded to the leak detection of the xBar system.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
11/03/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Colorectal Surgery, Anastomotic Leak
Register for Updates
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities
NCT06168968
Recruiting
The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke. Participants will engage in laboratory testing and health outcome assessments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
Register for Updates
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Johns Hopkins University Medical Center - 1627, Baltimore, Maryland
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
NCT04797286
Recruiting
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Scleroderma, Mildly Elevated Pulmonary Pressures
Register for Updates
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832
Recruiting
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
11/01/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Type1 Diabetes Mellitus
Register for Updates
The Effects of Fluoxetine And/or DHEA
NCT03228732
Recruiting
(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
11/01/2024
Locations: University of Maryland, Baltimore, Maryland
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)
NCT06671132
Recruiting
The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain \[CBOT-Pain (or CBOT-P)\] from Phase I, compared to sham Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) in Chronic Low Back Pain (CLBP) to determine its short- and long-term effectiveness on Pain, Negative Affect (NA), Cognition and Cortical Brain Structure (PACS), long-t... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/30/2024
Locations: Global Pain Management LLC, Pasadena, Maryland
Conditions: Chronic Pain, Low Back Pain
Register for Updates
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
NCT06311708
Recruiting
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
10/30/2024
Locations: John Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Christiana Care - Union Hospital, Elkton, Maryland
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
NCT05711485
Recruiting
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
10/29/2024
Locations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Severe Malaria, Thrombocytopenia
Register for Updates
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
NCT05450965
Recruiting
This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma
Register for Updates